Healthcare: Why Marijuana Stock HEXO Is on the Hot Seat. And, What's Behind Mylan's Mega-Merger With Pfizer
Pot stock HEXO is under fire over its use of social media advertising and if that isn't bad enough, its home province, Quebec, has proposed restrictions on marijuana edibles that could disrupt its growth plans. Is it game over for HEXO? Also, here's why biopharma giant Pfizer is merging its off-patent drug portfolio with generic drug heavy weight Mylan. Check out more of our content here: TMF's podcast portal YouTube Twitter Join Our Motley Fool Podcast Facebook Group LinkedIn StockUp, The Motley Fool's weekly email newsletter